Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096588 · ClinicalTrials.gov registry record · Phase 2
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02096588 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 34 participants.
The verdict
NCT02096588, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines. Anthracyclines may cause heart damage that can lead to weakening of the heart muscle. This heart damage may happen right away or may occur many years after the anthracycline is given Simvastatin is an oral medication approved by the FDA to lower cholesterol. Simvastatin is in a class of medications called statins. Some research has shown that statins may prevent heart damage that can be caused by anthracyclines like Doxorubicin (Adriamycin). The purpose of this study is to determine if taking simvastatin while receiving the chemotherapy Doxorubicin (Adriamycin) will minimize damage to the heart. This study is for women who will be receiving the anthracycline doxorubicin (Adriamycin) as part of their breast cancer treatment.
Interventions
- DRUG Simvastatin
- DRUG Doxorubicin/cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-05-20 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02096588
The ClinicalTrials.gov registry entry for NCT02096588 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Simvastatin is the first listed.
NCT02096588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02096588 about?
NCT02096588 is a clinical study titled "Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin". Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines. Anthracyclines may cause heart damage that can lead to weakening of the heart muscle. This heart damage may happen right away or may occur many years after...
What is the current status of trial NCT02096588?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2014-05-20. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT02096588?
The interventions under investigation include: Simvastatin (DRUG), Doxorubicin/cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT02096588?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.